Channon Monroe has over 18 years of experience in Clinical Research, Health Communications, Health Education, and Health Disparities. Her extensive knowledge and expertise reflect a passionate commitment to driving change in internal and external behaviors, enhancing understanding of disease disparities, and amplifying impact on diverse populations.

Channon's extensive professional background spans various roles within the industry and clinical research organizations, including Clinical Research Monitoring, Clinical Operations Management, Global Drug Safety, and Medical Device Sales.

Channon values the freedom and creativity in improving and enhancing collaborative partnerships with internal/external stakeholders and has demonstrated a deep commitment to advocating for underrepresented populations within Infectious Disease, Vaccine, Neuroscience, and Oncology clinical trials.

A change agent, Channon has been active in professional and community-based organizations, such as SLK Health Services Corporation, Healthcare Businesswomen's Association, and serving as a COVID-19 Community Ambassador for the Virginia Department of Health. She has received various awards, including HBA Spark Award and the Honored Volunteer Award, showcasing her exceptional contributions to the industry.

Channon earned a Bachelor of Science in Nursing from Hampton University (Hampton, VA), a Master of Science in Health Administration, and a Master of Science in Health Education - both from Saint Joseph’s University (Philadelphia, PA).

tbd

tbd

As Vice President and Head of Digital Development at Genmab, Chris Velas oversees a multidisciplinary team responsible for transforming development operations through innovative digital solutions. His leadership has redefined organizational workflows, enhanced trial insights, and implemented cutting-edge technologies, positioning the company as a leader in its field. Notable achievements include the successful implementation of multiple platforms which have enhanced the efficiency of our operations team and execution of multiple comprehensive digital strategies, the integration of AI-powered analytics, and significant advancements in programming and digital system oversight.

Velas is an accomplished leader with extensive experience leading digital transformation initiatives in biotechnology and life sciences. With a strong background in developing successful scalable digital strategies and fostering collaborations across cross-functional teams, Velas has been instrumental in driving innovation, operational efficiency, and compliance within fast-paced, growth-oriented organizations. His career at Genmab spans 5 years of delivering exceptional results through strategic leadership and expertise in programming, digital systems and data science applications while currently exploring AI possibilities for future growth while being fiscally responsible.

Velas holds a BS in Mathematics & Secondary Education from Kutztown University and has a commercial helicopter license.

tbd

tbd

Carrie Lewis has over 20 years of varied Clinical Research experience. Ms Lewis is currently an Executive Director, Clinical Program Optimization at Endo where she oversees Clinical Operations, Business Operations, eTMF/Inspectional Readiness, Training/Oversight, Medical Affairs Operations, Clinical Supplies, and Data Management. Prior to Endo, Ms Lewis garnered extensive knowledge in many roles while in academia, at large sponsors, generic sponsor, as well as a global CRO. She has a Master’s Degree in Clinical Research Administration and has experience in multiple therapeutic areas.

With over 25 years of experience in the clinical research industry, Suzy Montanye has dedicated 19 years as a Site Director at a private research clinic, where she successfully oversaw the completion of more than 150 clinical trials across 50 indications. Currently, she serves as a Site Relationship Manager, where she supports both seasoned and novice sites in navigating the complexities of running clinical trials. My role involves close collaboration with site teams and sponsor clinical teams to ensure that the site’s perspective is integrated into every aspect of the trial, fostering smoother and more effective study execution.

Parthi is an Innovation Lead with the vaccines business unit of Sanofi. In this role, he engages with early-stage innovators and entrepreneurs via a sponsored research framework to help groom emerging ideas into matured licensable products. Parthi also contributes to the broader Boston Innovation Ecosystem as a judge, mentor, and/or a grant reviewer for organizations such as Mass Innovation Network, Mass Life Sciences Center, and Mass Ventures. In his previous industry roles, Parthi has helped first-hand in the generation of more than $10M in revenue across 5 different product lines while working with the sales and business development teams of 2 different life sciences tools companies (Bio-techne and Quanterix) as a technical expert. Before moving to the industry, he was a research assistant professor at the University of Central Florida working on developing alternatives to antibiotics. He has published over 30 scientific articles including 3 patents. The recombinant vaccine platform developed as part of his PhD dissertation work won the AVMA award for the perceived impact in containing microbial resistance. Parthi holds a PhD in infectious diseases and immunology from Virginia Tech and a BVSc (Doctor of Veterinary Medicine) from Madras Veterinary College.

Mateja Kramer received her bachelor’s degree in microbiology in 2002, followed by a master’s degree in 2005 and a doctoral degree in 2010 from the University of Ljubljana, Faculty of Pharmacy, Slovenia, in the field of rapid microbiological technologies. She moved in 2002 to the Microbiology Analytical Science & Technology (AS&T) at Novartis, Slovenia, as a research fellow, and in 2010 became Head AS&T, responsible for managing microbiological quality systems, testing and release of the bulk and finished dosage forms. In 2015, she joined Novartis solid dosage forms Packaging site in Lendava, Slovenia, where she was responsible for a batch certification and release. In 2018, she joined Technical Research Development Biologics and Cell & Gene Therapies where she was responsible for managing innovation projects. Currently, she is a Global Head of Innovation in Technical Research Development responsible for leading the global enterprise innovation system across the drug development process for both biologics and chemical molecules. She has authored and co-authored 16 publications and mentored over 10 graduate students and research fellows. For 13 years she was an Expert in Water for pharmaceutical purposes nominated by European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe. She received the Best of the Best business practice award 2022 granted by the American Chamber of Commerce. Under her leadership, Innovation Council received the 2024 Innovation Impact Award for the best sustainable innovation program.

Alessio Bonati is the Director Alba & Nexa Flex Programs for DCS Business Unit (Drug Containment Solutions) at Stevanato Group, specialized in drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries. Mr. Bonati holds a Master's Degree in Electronic Engineering from the University of Ferrara (Italy) and an MBA from Bologna Business School (Italy). He has worked for multinational companies in several different businesses; in Stevanato Group since 2016, he has held different managerial roles, in the area of ​​product portfolio management and research and development. His current role involves the global management of the two high-end syringe platforms of Stevanato Group: Alba (glass syringe) and Nexa Flex (CoC/CoP syringe).

Charlotte Moser, MD, PhD, MBA, is Chief Medical Officer for Parexel. In this role Dr. Moser leads the company’s Global Medical Services (GMS) team in providing medical and scientific leadership globally, building on Parexel’s regulatory and therapeutic expertise with a significant focus on innovative drug development strategies and clinical trial design.

Dr Moser is a (radiation) oncologist who has worked as a clinician and researcher for more than 25 years and across both drug (small molecule, biological and targeted agents) and medical device (diagnostics, biomarkers, software) development. Her experience includes serving as head of clinical development at biotechnology and life sciences companies, bringing her clinical expertise to the early development of targeted oncology diagnostics and therapeutics and working closely with global regulators to support the approval of new therapies. She brings a unique combination of strategic clinical development leadership as well as experience as a principal investigator.

Dr Moser most recently served as Senior Vice President, Clinical Development for Celcuity, a clinical-stage biotechnology company focused on development of targeted therapies for treatment of multiple solid tumor indications.

Dr Moser earned an MD from Vrije University Amsterdam. She completed oncology training and earned a PhD in Biostatistics at the University of Leiden in The Netherlands. Dr. Moser also earned an MBA from the MIT Sloan School of Management and a certificate in drug development (Oncology and Cancer Biology) from Harvard Medical School. She is a strong advocate for innovation, driving better safety and efficiency in cancer care and improvement of global access.